255 related articles for article (PubMed ID: 30293754)
1. Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP).
Gaudio F; Mazza P; Carella AM; Mele A; Palazzo G; Pisapia G; Carluccio P; Pastore D; Cascavilla N; Specchia G; Pavone V
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):35-40. PubMed ID: 30293754
[TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.
Gaudio F; Mazza P; Mele A; Palazzo G; Carella AM; Delia M; Pisapia G; Pastore D; Cascavilla N; Pavone V; Specchia G
Ann Hematol; 2019 Jun; 98(6):1449-1455. PubMed ID: 30868307
[TBL] [Abstract][Full Text] [Related]
3. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.
Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G
Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892
[No Abstract] [Full Text] [Related]
5. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Peggs KS; Blaise D; Afanasyev B; Diez-Martin JL; Sierra J; Bloor A; Martinez C; Robinson S; Malladi R; El-Cheikh J; Corradini P; Montoto S; Dreger P; Sureda A
Br J Haematol; 2018 Apr; 181(1):86-96. PubMed ID: 29468647
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
Anderlini P; Saliba RM; Ledesma C; Plair T; Alousi AM; Hosing CM; Khouri IF; Nieto Y; Popat UR; Shpall EJ; Fanale MA; Hagemeister FB; Oki Y; Neelapu S; Romaguera JE; Younes A; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1333-1337. PubMed ID: 27064056
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation.
Jeong SH; Song HN; Park JS; Yang DH; Koh Y; Yoon SS; Lee HW; Eom HS; Won JH; Kim WS; Kim SJ
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2471-2478. PubMed ID: 30064012
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
[TBL] [Abstract][Full Text] [Related]
11. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Genadieva-Stavrik S; Boumendil A; Dreger P; Peggs K; Briones J; Corradini P; Bacigalupo A; Socié G; Bonifazi F; Finel H; Velardi A; Potter M; Bruno B; Castagna L; Malladi R; Russell N; Sureda A
Ann Oncol; 2016 Dec; 27(12):2251-2257. PubMed ID: 28007754
[TBL] [Abstract][Full Text] [Related]
12. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
[TBL] [Abstract][Full Text] [Related]
13. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
14. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
[TBL] [Abstract][Full Text] [Related]
15. Human Leukocyte Antigen-Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Analysis.
Lacerda MP; Arrais Rodrigues C; Pereira AD; Novis Y; Fonseca M; Silva RL; Macedo MCMA; Hamerschlak N; Esteves I; Schmidt Filho J; Nascimento MM; Rocha V
Biol Blood Marrow Transplant; 2017 Apr; 23(4):705-707. PubMed ID: 28108270
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Blaise D; Peggs KS; Afanasyev B; Diez-Martin JL; Corradini P; Michonneau D; Robinson S; Gutiérrez García G; Bonifazi F; Yakoub-Agha I; Gülbas Z; Bloor A; Delage J; Esquirol A; Malladi R; Scheid C; El-Cheikh J; Ghesquières H; Montoto S; Dreger P; Sureda A
Cancer; 2019 Jan; 125(1):90-98. PubMed ID: 30351488
[TBL] [Abstract][Full Text] [Related]
17. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
19. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
Devetten MP; Hari PN; Carreras J; Logan BR; van Besien K; Bredeson CN; Freytes CO; Gale RP; Gibson J; Giralt SA; Goldstein SC; Gupta V; Marks DI; Maziarz RT; Vose JM; Lazarus HM; Anderlini P
Biol Blood Marrow Transplant; 2009 Jan; 15(1):109-17. PubMed ID: 19135949
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.
Todisco E; Castagna L; Sarina B; Mazza R; Anastasia A; Balzarotti M; Banna G; Tirelli U; Soligo D; Santoro A
Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
